Research Article

Hub Gene Screening and Prognostic Modeling of Lung Cancer: An Integrated Bioinformatics Study

Henan Bai1 and Xiangdong Huang2

1Department of Oncology, Chifeng City Hospital, Chifeng, Inner Mongolia, China
2Department of Thoracic Surgery, Chifeng Hospital, Inner Mongolia, China

Correspondence should be addressed to Xiangdong Huang; hxd1116@126.com

Received 30 April 2022; Accepted 16 June 2022; Published 5 July 2022

Academic Editor: Ahmed Faeq Hussein

Copyright © 2022 Henan Bai and Xiangdong Huang. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. One of the most frequent malignancies is lung carcinoma which poses heavy burden on the global health. The link among differentially expressed genes (DEGs) and lung cancer patients’ clinical outcomes was still missing. In this study, we integrated transcriptome data with clinical data to investigate the relationship between them in lung carcinoma patients.

Methods. To begin, DEGs were identified using the Gene Expression Omnibus (GEO) gene expression pattern (GSE180347). Then, these DEGs are being searched in the TCGA database using the DEGs collected in the preceding phase. The Kaplan-Meier plotter was then used to assess the predictive value of these DEGs in patients with lung cancer.

Results. Our study revealed a total of 45 DEGs, 15 of which were up-regulated and 30 of which were down-regulated. These DEGs were mostly enriched in cytokine receptor binding and cytokine activity, according to GO enrichment analysis. These DEGs were mostly enriched in cytokine-cytokine receptor interaction, according to KEGG enrichment analysis. Based on the PPI network, which comprises of 12 DEGs, a major module was discovered. They are mostly interested in cytotoxicity mediated by natural killer cells. Among all 45 DEGs, the mutations of NCAM1 account for the most cases in TCGA database with a percentage above 15%. Among the 12 DEGs in the significant module, higher expression of FAS, GPR29, HAVCR2, and NCAM1 exhibits longer survival time with hazard ratio and 95% confidence interval of 0.79 (0.69-0.89), 0.80 (0.70-0.90), 0.71 (0.60-0.84), and 0.73 (0.62-0.86), respectively. However, higher expression of FCGR3A and IFNG exhibits shorter survival time with hazard ratio and 95% confidence interval of 1.50 (1.32-1.71) and 1.15 (1.02-1.31), respectively. Conclusion. Our results demonstrate significant correlation between some DEGs and the survival outcome in lung adenocarcinomas patients, providing a comprehensive bioinformatics study in anticipation of future molecular mechanisms and biomarker studies.

1. Introduction

Lung tumor is a malignancy that starts in the bronchial mucosa or glands of the lungs and is one of the most dangerous cancers for people’s health and lives [1]. Lung cancer death rates have increased dramatically in many countries during last 50 years [2]. In males, lung cancer has the highest incidence and mortality rate, whereas in females, tumor has the second highest incidence and mortality rate [3]. Despite the fact that the specific causation of lung cancer is unknown, a large body of research supports a strong relationship between long-term smoking and lung cancer [4]. Long-term cigarette smokers have such a 10- to 20-fold higher risk of lung carcinoma compared to nonsmokers, according to existing studies, and the earlier the age of smoke, the greater the incidence of cancer. Moreover, smoke has a detrimental effect not just on one’s own health but also on health of others around them, leading to a rise in the incidence of disease among latent smokers [5, 6].

CD274, also known as PDL1, is a ligand that binds to the T-cell receptor PD1 and inhibits T-cell activation by binding to it. PD1 expression has been seen in melanoma and non-small-cell pulmonary cancer [7]. The interplay of PD1/PDL1 is thought to be a way for tumors to evade the immune system. Several checkpoint blockade drugs targeting the PD1/PDL1 interface have been developed in order
to enable T-cells to detect tumor cells without being silenced by the tumor [8, 9]. Infiltration is the basic biological hallmark of malignant tumors, and immunological invasion of tumor cells is metastatic [10]. Malignant tumors have the capacity to penetrate and spread, which would be a biological feature. Since it is an invasive cancer, early detection, diagnosis, and treatment are very important in clinical practice. The characteristics of innate immune infiltration and related lung cancer marker genes may provide novel insights into lung disease immunotherapy [11].

In the present study, the mutations of critical genes play an important impact in the common development mechanism of lung cancer and will affect immunotherapy and chemotherapy, as well as the efficacy of medicine [12]. The relationship between differentially expressed genes and the clinical outcomes of lung cancer patients was still demanded to be explained. The sharing of transcriptome data and the development of new bioinformatics analysis tools have enabled us to integrate transcriptome data with clinical data to investigate the relationship between them in lung cancer development. This can help us understand the development of lung cancer from both perspectives and could offer fresh insights into the disease’s prophylaxis and management.

2. Material and Methods

2.1. Data. The gene expression characteristics (GSE180347) have been retrieved from the Gene Expression Omnibus
| Gene   | Name                                      | Synonyms                                                                 | Chromosome | Category                                           |
|--------|-------------------------------------------|---------------------------------------------------------------------------|------------|---------------------------------------------------|
| BIRC5  | Baculoviral IAP repeat containing 5       | API4|EPR-1                                                                  | 17         | Antimicrobials                                    |
|        | C-C motif chemokine ligand 13             | CKb10|MCP-4|NCC-1|NCC1|SCYA13|SCYL1                                                | 17         | Antimicrobials, chemokines, and cytokines             |
| CCL13  |                                          | CC-1|CC-3|CKB1|HCC-1|HCC-1-1(74)|HCC-1-3|HCC-3|MCIF|NCC-2|NCC2|SCYA14|SCYL2|SY14                                             | 17         | Antimicrobials, chemokines, and cytokines             |
| CCL14  |                                          | BN-1|C-C|CKR-6|CC-CKR-6|CCR-6|CD196|CD91|CMKBR6|DCR2|DRY6|GPR29|GPYRCY4|STRL22                                             | 6          | Antimicrobials, chemokine receptors, and cytokine receptors |
| CCR6   |                                          | CD209 molecule                                                            | 19         | Antigen processing and presentation                |
|        | CD70 molecule                             | CD27-L|CD27L|CD27LG|LPFS3|TNFSF5|TNNLG8A                                               | 19         | Cytokines                                           |
| CR2    | Complement C3d receptor 2                 | C3DR|CD21|CR|CVID7|SLEB9                                               | 1          | BCR signaling pathway                               |
| CSF2   | Colony stimulating factor 2               | CSF|GMCSF                                                        | 5          | Cytokines, natural killer cell cytotoxicity, and TCR signaling pathway |
| CXCL10 | C-X-C motif chemokine ligand 10           | C7|IFI10|INP10|IP-10|SCYB10|crg-2|gIP-10|mob-1                                             | 4          | Antimicrobials, chemokines, and cytokines             |
| FAS    | Fas cell surface death receptor            | ALPS1A|APO-1|APT1|CD95|FAS1|FASTM|TNFRSF6                                              | 10         | Natural killer cell cytotoxicity                     |
| FCGR3A | Fc fragment of IgG receptor IIIa          | CD16|CD16A|FCG3|FCGR3|FCGRIII|FCR-10|FCR1II|FCR1IIA|IGFR3|IMD20                                               | 1          | Natural killer cell cytotoxicity                     |
| FPR2   | Formyl peptide receptor 2                 | ALXR|FMLP-R-II|FMLP|X|FPR2A|FPRH2|FPR1|HM63|LXA4R                                               | 19         | Chemokine receptors and cytokine receptors             |
| GNLY   | Granulysin                                | D2S69E|LAG-2|LAG2|NKG5|TLA519                                               | 2          | Antimicrobials                                      |
| GZMB   | Granzyme B                                | C11|CCP1|CGL-1|CGL1|CSPB|CSBP|CTLA1|CTSL1|HL|HP|SCP-B|STRTA|SECT                                               | 14         | Natural killer cell cytotoxicity                     |
| IFNG   | Interferon gamma                          | IFG|IFI                                                      | 12         | Antigen processing and presentation, antimicrobials, cytokines, interferons, natural killer cell cytotoxicity, and TCR signaling pathway |
| IFNL1  | Interferon lambda 1                       | IL-29|IL29                                                   | 19         | Antimicrobials, cytokines, and interleukins         |
| IL1RA  | Interleukin 11 receptor subunit alpha      | CRSDA                                                      | 9          | Cytokine receptors and interleukin receptor         |
| IL1A   | Interleukin 1 alpha                        | IL-1 alpha|IL-1A|IL1|IL1-ALPHA|IL1F1                                                 | 2          | Antimicrobials, cytokines, and interleukins         |
| IL1RN  | Interleukin 1 receptor antagonist          | DIRA|CIL-1R|IL-1RN|IL-1ra|IL-1ra3|IL1F3|IL1RA|IRAP|MVCD4                                               | 2          | Cytokines and interleukins                           |
| ISG15  | ISG15 ubiquitin like modifier             | G1P2|IF15|IMD38|IP17|UCRP|hUCRP                                               | 1          | Antimicrobials                                      |
| KLRD1  | Killer cell lectin like receptor D1        | CD94                                                      | 12         | Antigen processing and natural killer cell cytotoxicity |
| PLAU   |                                          | ATF|BDPLT5|QP|UPA|URK|u-PA                                                 | 10         | Antimicrobials, chemokines, and cytokines            |
and used as discovery datasets to recognize differential expression in 34 cases with high total immune cell infiltration (PH) and 7 cases with low total immune cell infiltration (PC) (DEGs).

2.2. Identification of DEGs. DEGs were identified using R’s LIMMA package [13, 14]. Instead, to avoid the appearance of false-positive results, adjusted $P$ values (adj $P$ value) were produced. DEGs between PH and PC samples were defined as genes with $|\log_2$ fold change (FC)$| > 1$ and adj $P$ value 0.01. IMMPORT (https://www.immport.org/resources) was used to uncover prospective immunotherapy targets by searching for related immune genes.

2.3. GO and KEGG Enrichment Analyses. Using the R packages clusterProfiler and pathview, which are designed to automate biological-term classification and enrichment analysis of gene clusters, the DEGs were analyzed for GO (Gene Ontology) and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway enrichment.

2.4. PPI Network Construction. The DEGs’ protein-protein interactions (PPIs) were calculated using the search tool for the retrieval of interacting genes (STRING; https://string.embl.de/), which had a confidence score of 0.9 [15]. The PPI network was then visualized using the Cytoscape program (version 3.5.1). Furthermore, with default settings, the molecular complex detection (MCODE) plug-in in Cytoscape program was used to examine the key modules in the PPI network [16].

2.5. Survival Analysis of DEGs. Based on the DEGs obtained from the previous step, these DEGs were searched in The Table 1: Continued.

| Gene Name | Synonyms | Chromosome | Category |
|-----------|----------|------------|----------|
| Plasminogen activator: urokinase | EAT2 | 1 | Natural killer_cell_cytotoxicity |
| SH2D1B | SH2 domain containing 1B | BNSP|BSP1|ETA-1|OPN | 4 | Cytokines |
| SPP1 | Secreted phosphoprotein 1 | CANDF7|IMD31A|IMD31B|IMD31C|ISGF-3|STAT91 | 2 | Antimicrobials |

Figure 2: The enriched GO terms of DEGs in GSE180347.
Cancer Genome Atlas (TCGA) database using the combinations of keywords. Based on the recovered cases, the Kaplan-Meier plotter (http://kmplot.com/analysis) might be used to assess the prognostic value of these DEGs in lung adenocarcinoma patients.

2.6. Statistical Analysis. Continuous normally distributed data are expressed as means ± SDs. All statistical calculations were carried out using SPSS statistical software. Multiple comparisons were analyzed via analysis of variance (ANOVA). \( P \) values < 0.05 were considered significant.

3. Results

3.1. Differentially Expressed Genes (DEGs). DEGs were identified using gene expression profiles (GSE180347), which consisted of 34 cases with tumors expressing PD-L1 and high total immune cell infiltration (PH) and 7 instances with tumors expressing PD-L1 and low total immune cell infiltration (PC). Our study revealed a total of 45 DEGs, 15 of which were upregulated and 30 of which were downregulated (Figure 1 and Table 1). The 15 upregulating genes were CD55, IFNL1, FCER2, CD34, C6, BLK, TLR5, IL11RA, AMBP, PLA2G1B, NCAM1, CR2, TLR10, CCR6, and CCL14 in descending order of log FC. The 30 downregulating genes were STAT1, PLAU, CDK1, IL1A, ISG15, FPR2, TTK, CD209, SH2D1B, FAS, FCGR3A, CSF2, IFNG, MEFV, HAVCR2, PBK, BIRC5, LILRA5, GNYL, GZMH, SPP1, F12, KLRD1, CD70, CCL13, GZMB, ITGB3, CXCL10, and CLEC5A. Of those 45 DEGs, 25 DEGs were identified as immune-related genes (Table 1). Their functions can be classified as antimicrobials, chemokines, cytokines, chemokine receptors, cytokine receptors, BCR signaling pathway, TCR signaling pathway, and so on.

3.2. Functional Enrichment Analysis of DEGs. These DEGs were enriched across several aspects, of which the most significant was cytokine receptor binding, cytokine activity, and virus receptor activity. Besides, exogenous protein binding, receptor ligand activity, signaling receptor activator activity, interleukin-1 receptor binding, immune receptor activity, and signaling receptor activator activity were also differently expressed (Figure 2). These DEGs were shown to be enriched in multiple pathways according to KEGG enrichment analysis (Figure 3). The most important one is cytokine-cytokine receptor interaction, hematopoietic cell lineage, and graft-versus-host disease.

3.3. Protein-Protein Interaction Network. The PPI network was built using STRING, and the most important modules in the network were identified using Cytoscape software. The protein-to-protein interaction network of DEGs was complicated in the regulation system, as shown in Figure 4. Genes with high degrees were chosen for further investigation. MCODE discovered a substantial module with 12 nodes and 110 edges (Table 2). The module consists of 12 DEGs,
including FAS, STAT1, IFNG, TLR10, CSF2, FCGR3A, HAVCR2, CXCL10, GPR29, GZMB, CD34, and NCAM1. Of the 12 DEGs, FCGR3A is the seeded genes and has the largest degree. TLR10 has the lowest degree. The average degree of the 12 DEGs is 30.5 and the average score is 6.95. They are enriched into several KEGG pathways, including natural killer cell-mediated cytotoxicity, allograft rejection, graft-versus-host disease, type I diabetes mellitus, and so on. The identified 12 DEGs were used for downstream survival analysis.

### 3.4. Survival Analysis of DEGs

The total of 45 DEGs obtained from the previous step was retrieved in the TCGA database. Finally, 248 relevant cases were identified. Among them, there were 102 female cases and 129 male cases. Following the period, 79 cases were dead, while 150 cases are still alive, and 2 cases were not reported. Among the 248 cases, the mutations of NCAM1 account for the most; the following are C6, CR2, and TTK. The GZM8 accounts for the least and then comes the SPP1 (Figure 5). As a result, mutations in the NCAM1 gene were by far the most prevalent. The prognostic of 12 DEGs in the most significant module was explored through the Kaplan-Meier plotter (Figure 6). Higher expression of FAS, GPR29, HAVCR2, and NCAM1 in lung carcinoma patients exhibit longer survival time with hazard ratio and 95% confidence interval of 0.79 (0.69-0.89), 0.80 (0.70-0.90), 0.71 (0.60-0.84), and 0.73 (0.62-0.86), respectively. However, higher expression of FCGR3A and IFNG in lung carcinoma patients exhibits shorter survival time with hazard ratio and 95% confidence interval of 1.50 (1.32-1.71) and 1.15 (1.02-1.31), respectively.
Nonetheless, the expression of the other six DEGs (STAT1, TLR10, CSF2, CXCL10, GZMB, and CD34) did not affect the survival outcome of the lung cancer patients.

4. Discussion

The DEGs among high and low total immune cell infiltration in lung carcinoma patients expressing PD-L1 were studied in this research. This study is meaningful since transcriptome data (clinical) were integrated for investigating potential value (prognostic) of DEGs between high and low total immune cell infiltrations in lung carcinoma patients expressing PD-L1. This research can be used to better understand the predictive value of differently altered and to develop clinical diagnoses and treatments.

Our research found 45 DEGs, with 15 upregulated genes and 30 downregulated genes. These DEGs were primarily enriched in cytokine receptor binding and cytokine activity, according to GO enrichment analysis. These DEGs were primarily enriched in cytokine-cytokine receptor interaction, according to KEGG enrichment analysis. By attaching to specific cytokine receptors on the cell surface, cytokines execute biological functions [17]. When a cytokine attaches to its receptor, signal transduction mediated by cytokines begins. Transmembrane proteins contain extracellular, transmembrane, and cytoplasmic domains, which make up the vast majority of cytokine receptors discovered thus far. Cytokines have a broad variety of biological features, including trying to promote target cell proliferation and differentiation, improving anti-infection and cell killing effects, promoting or inhibiting the expression of other cytokines and membrane surface molecules, promoting inflammatory processes, and affecting cell metabolism [18]. A significant module was identified based on the PPI network, which consists of 12 DEGs. Natural killer cell-mediated cytotoxicity is where they are usually found. Among all the 45 DEGs, the mutations of NCAM1 account for the most cases in TCGA database with a percentage above 15%. Importantly, NCAM1 was reported to be a CSC marker and a therapeutic target in solid tumors. NCAM1 was also highly expressed in lung cancer.

Among the 12 DEGs in the significant module, higher expression of FAS, GPR29, HAVCR2, and NCAM1 exhibits longer survival time. However, higher expression of FCGR3A and IFNG exhibits shorter survival time. FAS codes for a member of the TNF-receptor family of proteins [19]. This receptor contains a death domain. It has been discovered to have an important function in the physiologic control of cell death as well as the pathology of a number of immune system malignancies and diseases. FAS-AS1 was significantly downregulated in NSCLC cells. FAS-AS1 could also inhibit cell proliferation, migration, and invasion in NSCLC cells. GPR29 is a beta chemokine receptor with a seven-transmembrane structure that is similar to G protein-coupled receptors [20]. The GPR29 gene is only expressed by immature dendritic cells and memory T-cells. HAVCR2 is a member of the immunoglobulin superfamily as well as the TIM protein family [21]. This Th1-specific cell surface protein modulates macrophage activation, suppresses Th1-mediated auto- and alloimmune responses, and promotes immunological tolerance. NCAM1 is a cell adhesion protein that belongs to the immunoglobulin superfamily [22]. During development and differentiation, the encoded protein is engaged in cell-to-cell as well as cell-matrix interactions. The encoded protein regulates neurogenesis, neurite outgrowth, and cell migration during nervous system development. FCGR3A is a receptor for the Fc component of immunoglobulin G that is involved in the removal of antigen-antibody complexes from circulation as well as other reactions such antibody-dependent cellular mediated cytotoxicity and antibody-dependent intensification of virus infections [23]. The soluble cytokine IFNG belongs to the type II interferon class [24]. The cells from both the innate and adaptive immune systems release the encoded protein. The active protein is a homodimer that binds to the interferon gamma receptor, which initiates a cellular response in response to viral and microbial infections. This gene mutation has been linked to an increased vulnerability to viral, bacterial, and parasite infections, as well as a variety of autoimmune disorders.
The advantage of this study was to identify the related genes that can affect the survival of lung cancer. However, some limitations should be acknowledged. First, only one dataset was added in examination, without considering the effect of population heterogeneity among different countries on the results. Second, the lack of verifiable datasets in this study limits the extrapolation of research results. Third, this study is only for the reanalysis of existing data and lacks the

![Graphs showing survival analysis for different genes](image)

**Figure 6:** Prognostic of the critical DEGs in lung carcinoma patients.
support and verification of experimental data. Finally, our findings give a complete bioinformatics study of high and low total immune cell infiltration in lung cancer patients who express PD-L1, which may aid in the knowledge of lung carcinoma formation, prevention, and treatment.

Data Availability

The data could be obtained from contacting corresponding author.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] B. C. Bade and C. S. Dela Cruz, "Lung cancer 2020: epidemiology, etiology, and prevention," *Clinics in Chest Medicine*, vol. 41, no. 1, pp. 1–24, 2020.

[2] Y. Mao, D. Yang, J. He, and M. J. Krasna, "Epidemiology of lung cancer," *Surgical Oncology Clinics of North America*, vol. 25, no. 3, pp. 439–445, 2016.

[3] S. Frega, A. Dal Maso, A. Ferro, L. Bonanno, P. Conte, and G. Pasello, "Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): do gender and sex matter?," *Critical Reviews in Oncology/Hematology*, vol. 138, pp. 87–103, 2019.

[4] H. S. Karagueuzian, C. White, J. Sayre, and A. Norman, "Cigarette smoke radioactivity and lung cancer risk," *Nicotine & Tobacco Research*, vol. 14, no. 1, pp. 79–90, 2012.

[5] M. Hori, H. Tanaka, K. Wakai, S. Sasazuki, and K. Katanoda, "Secondhand smoke exposure and risk of lung cancer in Japan: a systematic review and meta-analysis of epidemiologic studies," *Japanese Journal of Clinical Oncology*, vol. 46, no. 10, pp. 942–951, 2016.

[6] H. Lee, Y. Lu, Y. Huang, S. L. Huang, and H. Chuang, "Air pollution effects to the subtype and severity of lung cancers," *Frontiers in Medicine*, vol. 9, article 835026, 2022.

[7] L. Wang, Q. Ma, R. Yao, and J. Liu, "Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer," *International Immunopharmacology*, vol. 79, article 106088, 2020.

[8] D. Chen, H. B. Barsoumian, L. Yang et al., "SHP-2 and PD-L1 inhibition combined with radiotherapy enhances systemic antitumor effects in an anti-PD-1-resistant model of non-small cell lung cancer," *Cancer Immunology Research*, vol. 8, no. 7, pp. 883–894, 2020.

[9] D. Chen, H. B. Barsoumian, G. Fischer et al., "Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity," *Journal for Immunotherapy of Cancer*, vol. 8, no. 1, article e000289, 2020.

[10] J. Sun, Z. Zhang, S. Bao et al., "Identification of tumor immune infiltration-associated IncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer," *Journal for Immunotherapy of Cancer*, vol. 8, article e00110, no. 1, 2020.

[11] R. Zhong, D. Chen, S. Cao, J. Li, B. Han, and H. Zhong, "Immune cell infiltration features and related marker genes in lung cancer based on single-cell RNA-seq," *Clinical & Translational Oncology*, vol. 23, no. 2, pp. 405–417, 2021.

[12] Y. Wang, S. Zhou, Z. Zhao, P. Liu, C. Ke, and S. Xu, "New insights into small-cell lung cancer development and therapy," *Cell Biology International*, vol. 44, no. 8, pp. 1564–1576, 2020.

[13] I. Diboun, L. Wernisch, C. A. Orenge, and M. Kolzenburg, "Microarray analysis after RNA amplification can detect pronounced differences in gene expression using limma," *BMC Genomics*, vol. 7, no. 1, 2006.

[14] G. Yu, L. Wang, Y. Han, and Q. Y. He, "clusterProfiler: an R package for comparing biological themes among gene clusters," *Omnis: a journal of integrative biology*, vol. 16, no. 5, pp. 284–287, 2012.

[15] D. Szklarczyk, A. Franceschini, S. Wyder et al., "STRING v10: protein-protein interaction networks, integrated over the tree of life," *Nucleic Acids Research*, vol. 43, no. D1, pp. D447–D452, 2015.

[16] G. D. Bader and C. W. V. Hogue, "An automated method for finding molecular complexes in large protein interaction networks," *BMC Bioinformatics*, vol. 4, no. 1, p. 2, 2003.

[17] I. Moraga, J. Spangler, J. L. Mendoza, and K. C. Garcia, "Multifarious determinants of cytokine receptor signaling specificity," in *Advances in Immunology*, vol. 121, pp. 1–39, Elsevier, 2014.

[18] K. C. Conlon, M. D. Mlijkovic, and T. A. Waldmann, "Cytokines in the treatment of cancer," *Journal of Interferon & Cytokine Research*, vol. 39, no. 1, pp. 6–21, 2019.

[19] Z. Zhong-Xing, M. Yuan-Yuan, M. Hai Zhen, Z. Jian-Gang, and Z. Li-Feng, "FAS-1377 G/A (rs2234767) polymorphism and cancer susceptibility: a meta-analysis of 17, 858 cases and 24, 311 controls," *PLoS One*, vol. 8, no. 8, article e73700, 2013.

[20] Z. Wan, H. Xiong, X. Tan, T. Su, K. Xia, and D. Wang, "Integrative multi-omics analysis reveals candidate biomarkers for oral squamous cell carcinoma," *Frontiers in Oncology*, vol. 11, article 794146, 2022.

[21] Y. Huang, C. Zhu, Y. Kondo et al., "CEACAM1 regulates TIM-3-mediated tolerance and exhaustion," *Nature*, vol. 517, no. 7534, pp. 386–390, 2015.

[22] X. Zhang, F. Xu, and X. Y. Han, "siRNA-mediated NCAM1 gene silencing suppresses oxidative stress in pre-eclampsia by inhibiting the p38MAPK signaling pathway," *Journal of Cellular Biochemistry*, vol. 120, no. 11, pp. 18606–18617, 2019.

[23] J. Wu, Y. Li, W. Guan, K. Viken, D. M. Perlman, and M. Bhargava, "FCGR3A and FCGR3B copy number variations are risk factors for sarcoidosis," *Human Genetics*, vol. 135, no. 7, pp. 715–725, 2016.

[24] S. Wu, X. Liu, Y. Wang, M. Zhang, M. Wang, and J. He, "Genetic polymorphisms of IFNG and IFNγR1 with latent tuberculosis infection," *Disease Markers*, vol. 2019, Article ID 8410290, 7 pages, 2019.